Brain infusion upgrade: could a new method make Parkinson's treatment easier?
NCT ID NCT07215403
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new, faster method to deliver the drug AB-1005 into the brain of people with advanced Parkinson's disease. The goal is to see if the new approach can consistently reach the target area while being safer and quicker. 18 participants will be enrolled to assess the procedure's accuracy and safety over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AB-1005 (a drug delivered directly into the brain)
What this could lead to
If successful, this could make brain infusions for Parkinson's quicker and more reliable, potentially improving treatment delivery.
What could go wrong
This is a small, early-stage trial focused on the delivery method, not on whether the drug itself works. The procedure still carries risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE (DISORDER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Wexner Medical Center Neurological Surgery
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••